When patients and families start looking for access to an experimental treatment, the first question is often simple:
How long will this take?
The honest answer is: it depends on the pathway, the urgency of the case, and how quickly the key people move. But one thing is important to understand from the start: delays are not always caused by regulators. In many cases, the real timeline is shaped by physician readiness, manufacturer response, institutional review, and paperwork.
For patients with serious or life-threatening conditions, this distinction matters. When time is limited, understanding where the process actually slows down can make the entire pathway easier to navigate.
First, the timeline depends on which route you are using
If a patient is joining a clinical trial, the timing depends on trial screening, site availability, and eligibility. But if the patient is seeking access to an investigational treatment outside a trial, the most relevant pathway is usually single-patient expanded access, sometimes called compassionate use. This is the route the FDA describes for patients with serious or immediately life-threatening conditions when no comparable or satisfactory alternative is available.
That pathway can move on very different timelines depending on whether the situation is emergency or non-emergency. In an emergency, FDA authorization may be given by phone or other rapid communication, and treatment can begin before the written submission is formally completed. In a non-emergency case, treatment may generally proceed 30 days after FDA receives the submission,or earlier if FDA notifies the physician that treatment may begin sooner. FDA also notes that, in most cases, it completes review within a few days rather than using the full 30-day period.
So where does the time really go?
Patients often assume the FDA is the main bottleneck. Usually, that is not the full story.
Before a physician can even file a single-patient expanded access request, the manufacturer must agree to provide the investigational product. FDA says this explicitly: if the manufacturer will not supply the product, the pathway stops there. The physician also has to prepare the clinical rationale, treatment plan, informed consent, and the submission itself, usually through Form FDA 3926 for individual patient requests.
That means the real clock often starts before the FDA review clock starts. It starts when a physician identifies the product, reaches the company, gathers the required information, and gets institutional support in place. The Reagan-Udall Expanded Access Navigator’s checklist shows just how many moving parts may be involved even in a single-patient case: company documents, FDA forms, IRB materials, and follow-up reporting requirements.
Emergency cases can move very fast
In true emergencies, access can happen in hours, not weeks.
FDA guidance says emergency requests may be made by telephone or other rapid means, with authorization to ship and use the drug given before the written IND is submitted. FDA’s overview materials say emergency expanded access can begin once the use is authorized by the reviewing official.
But “fast” does not mean effortless. The treating physician still has to determine that the case meets emergency criteria, the manufacturer still has to agree, informed consent usually still has to be obtained, and institutional review board notification or follow-up may still be required depending on the circumstances. NIH and institutional IRB guidance both make clear that emergency use still sits inside a formal regulatory framework.
Non-emergency access is usually measured in days to weeks
For non-emergency single-patient access, the official framework sounds longer than it often is.
FDA says treatment may begin 30 days after it receives the IND submission unless the physician is notified earlier, and FDA’s own educational material notes that review is completed within a few days in most cases. A review article summarizing FDA practice similarly notes that non-emergency requests are often approved on average within about four days.
So why do patients still experience delay?
Because the FDA decision is only one part of the timeline. The physician must first secure company agreement, prepare the request, and obtain the required IRB approval and informed consent before treatment starts. NIH guidance also notes that even when only one patient is being treated, institutional oversight still applies.
IRB review is important, but it may not be as slow as people fear
IRB review is often perceived as a major obstacle, but the process has become more streamlined for many single-patient requests.
NIH explains that under FDA’s 2017 guidance, an IRB chair concurrence can in some cases replace full board review for individual patient expanded access requests when the physician is acting as sponsor-investigator. That can reduce procedural delay.
Research on IRB professionals suggests that many institutions are prepared to handle these requests. In one survey, most respondents said IRB review of single-patient expanded access was important, many supported review by a designated reviewer rather than the full board, and most felt their IRBs were prepared for these requests.
So, IRB review can add time, but it is not always the reason access stalls. Often, the harder step comes earlier: getting the request organized and getting the manufacturer to say yes.
For oncology patients, there may be a faster support route
Cancer patients may have an additional advantage in the US.
FDA’s Project Facilitate was created as a single point of contact to help oncology healthcare providers and regulatory professionals submit expanded access requests for individual patients with cancer. This does not eliminate the core requirements, but it can reduce confusion and speed up navigation for physicians who are unfamiliar with the process.
That matters because many delays are practical, not theoretical. A pathway can exist on paper and still be underused if physicians do not know where to start.
The real answer patients need
So, how long does it really take to get experimental treatment access?
In an emergency, it may move the same day once the right people act. In a non-emergency single-patient access case, the FDA piece may take only a few days in practice, even though the formal framework allows up to 30 days. But the full patient journey often takes longer because it includes company approval, physician preparation, IRB steps, consent, shipping, and treatment logistics.
That is why the better question is not only “How long does FDA take?” but also:
Who is helping move the process forward?
Because access timelines are often determined less by one official deadline and more by whether a physician, institution, and manufacturer are ready to act quickly together.
Final thought
When patients hear “experimental treatment access,” they often imagine one formal approval standing between them and treatment.
In reality, access is a chain.
And like any chain, it moves only as fast as each link.
The FDA timeline matters. But so do manufacturer response, physician initiative, IRB coordination, and operational follow-through. For patients in urgent situations, understanding that difference is not just informative. It can shape what to ask next, who to involve, and where to push for speed.